Dermatomyositis associated with capecitabine in the setting of malignancy.
Department of Dermatology, Stanford University School of Medicine, Stanford, California.
Frank W
FW
Chen
Department of Dermatology, Stanford University School of Medicine, Stanford, California.
Xiaolong
X
Zhou
Pathology Service, VA Palo Alto Health Care System, Palo Alto, California.
Barbara M
BM
Egbert
Department of Dermatology, Stanford University School of Medicine, Stanford, California; Dermatology Service, VA Palo Alto Health Care System, Palo Alto, California.
Susan M
SM
Swetter
Department of Dermatology, Stanford University School of Medicine, Stanford, California. Electronic address: ksarin@stanford.edu.
Kavita Y
KY
Sarin
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001707:Biopsy, Needle; D000069287:Capecitabine; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003882:Dermatomyositis / Q000139:chemically induced* / Q000473:pathology; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D018570:Risk Assessment; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil